SavedAdd your journal

Journals / Düzce Tıp Fakültesi Dergisi / 2009 / Cilt: 11 - Sayı: 1

Akut dekompanze kalp yetmezliği varlığında levosimendan tedavisi esnasında NT-pro BNP düzeyi ve sol ventrikül ejeksiyon fraksiyonununprognostik etkisinin değerlendirilmesi

The evaluation of the prognostic effect of NT-pro BNP levels and left entricular ejection fraction in acute decompansated heart failure during levosimendan treatment

Gülten Taçoy
Deniz DEMİR
Timur TİMURKAYNAK
Yusuf TAVİL
İbrahim IZGU
Erdem Güliz YAZICI
Pages
4–12
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Clinical status, systolic (SBP) and diastolic blood (DBP) pressures as hemodynamic parameters, measurements of serum NT-proBNP, BUN, Cre, Na+, K+, AST, ALT, Hb, Htc levels; left ventricular end diastolic (LVEDD) and systolic (LVESD) diameters, end diastolic (LVEDV) and end systolic (LVESV) volumes, cardiac output and ejection fraction (LVEF) by echocardiographic evaluation were obtained before and after levosimendan infusionResults: Treatment with levosimendan in decompansated heart failure exerts significantly reduction in LVEDD, LVEDV, LVESV, DBP, serum NT-proBNP levels and increase in LVEF (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To evaluate the prognostic effect of serum NT-proBNP levels and left ventricular ejection fraction in patients who have acute decompansated heart failure and receive levosimendan treatment.Method: Fourteen patients (10 male (71,4 %), 4 female (28,6%)) with heart failure who have low cardiac output findings and unresponsive to intravenous and vasodilator therapy, functional capacity NHYA class IV were enrolled into the study.
📊
Key Findings & Data:Aim: To evaluate the prognostic effect of serum NT-proBNP levels and left ventricular ejection fraction in patients who have acute decompansated heart failure and receive levosimendan treatment.Method: Fourteen patients (10 male (71,4 %), 4 female (28,6%)) with heart failure who have low cardiac output findings and unresponsive to intravenous and vasodilator therapy, functional capacity NHYA class IV were enrolled into the study.
💡
Conclusion & Impact:Clinical status, systolic (SBP) and diastolic blood (DBP) pressures as hemodynamic parameters, measurements of serum NT-proBNP, BUN, Cre, Na+, K+, AST, ALT, Hb, Htc levels; left ventricular end diastolic (LVEDD) and systolic (LVESD) diameters, end diastolic (LVEDV) and end systolic (LVESV) volumes, cardiac output and ejection fraction (LVEF) by echocardiographic evaluation were obtained before and after levosimendan infusionResults: Treatment with levosimendan in decompansated heart failure exerts significantly reduction in LVEDD, LVEDV, LVESV, DBP, serum NT-proBNP levels and increase in LVEF (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: To evaluate the prognostic effect of serum NT-proBNP levels and left ventricular ejection fraction in patients who have acute decompansated heart failure and receive levosimendan treatment.Method: Fourteen patients (10 male (71,4 %), 4 female (28,6%)) with heart failure who have low cardiac output findings and unresponsive to intravenous and vasodilator therapy, functional capacity NHYA class IV were enrolled into the study. Clinical status, systolic (SBP) and diastolic blood (DBP) pressures as hemodynamic parameters, measurements of serum NT-proBNP, BUN, Cre, Na+, K+, AST, ALT, Hb, Htc levels; left ventricular end diastolic (LVEDD) and systolic (LVESD) diameters, end diastolic (LVEDV) and end systolic (LVESV) volumes, cardiac output and ejection fraction (LVEF) by echocardiographic evaluation were obtained before and after levosimendan infusionResults: Treatment with levosimendan in decompansated heart failure exerts significantly reduction in LVEDD, LVEDV, LVESV, DBP, serum NT-proBNP levels and increase in LVEF (p

Özet

Amaç: Akut dekompanze kalp yetmezliği nedeniyle levosimendan tedavisi alan hastalarda serum NT-pro BNPdüzeyleri ve sol ventrikül ejeksiyon fraksiyonunun prognostik öneminin araştırılması.Yöntem: NYHA sınıflamasına göre sınıf IV fonksiyonel kapasiteye sahip, intavenöz ve vazodilatör tedaviyecevap vermeyen ve düşük kardiyak debi bulgularına sahip 14 kalp yetmezliği hastası ( 10 erkek (%71.4), 4 kadın(%28.6) çalışmaya dahil edildi. Klinik durum, hemodinamik parametreler olarak sistolik (SBP) ve diastolik kanbasıncı (DBP) değerleri, serum NT-pro BNP, BUN, kreatinin, Na+, K+, AST, ALT, Hb, Htc düzeyleri, ekokardiyografik olarak sol ventrikül diastol (LVEDD) ve sistol sonu çapları (LVESD) hacimleri, kardiyak debive ejeksiyon fraksiyonu (LVEF) parametreleri levosimendan tedavisi öncesi ve sonrasında elde edilerekkarşılaştırıldı.Bulgular: Dekompanze kalp yetmezliği varlığında, levosimendan tedavisi sol ventrikül diastol sonu çapı vehacmi, sol ventrikül sistol sonu hacmi, diastolik kan basıncı, serum NT-pro BNP düzeylerinde belirgin azalmayave sol ventrikül ejeksiyon fraksiyonunda artmaya neden olmuştur (p< 0.05). NT-pro BNP düzeyi ile solventrikül EF arasında anlamlı ters ilişki varlığı ortaya konmuştur (p

🔖

Cite This Article

Taçoy, G., DEMİR, D., TİMURKAYNAK, T., TAVİL, Y., IZGU, İ., YAZICI, E. G. (2022). Akut dekompanze kalp yetmezliği varlığında levosimendan tedavisi esnasında NT-pro BNP düzeyi ve sol ventrikül ejeksiyon fraksiyonununprognostik etkisinin değerlendirilmesi. Düzce Tıp Fakültesi Dergisi, Cilt: 11 - Sayı: 1, 4–12. https://ajindex.com/articles/493791

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Kopustinskiene DM, Pollesello P, Saris N: EL Levosimendan is a mitochondrial KATP channel opener. Eur J Pharmacol 428 (3): 311-4, 2001
  2. Follath F, Cleland JGF, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 360 (9328): 196-202, 2002
  3. Gardner RS, Özapl F, Murday AJ et al. N- terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 24:1735-1743, 2003
  4. Greenberg B, Borghi C, Perrone S: Pharmacotherapeutic approaches for decompensated heart failure: a role for the calcium sentitiser, levosimendan? Eur J Heart Fail. 5(1):13-21, 2003
  5. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM: Treatment of heart failure guided by plasma NTproBNP concentrations. Lancet 355(9210):1126-30, 2000
  6. Mebazaa A: The SURVIVE-W Trial: Comparison of Dobutamine and Levosimendan on Survival in Acute Decompensated Heart Failure. American Heart Association Scientific Sessions; Dallas, 2005
  7. Packer M. REVIVE II: Multicenter Placebo-Controlled Trial of Levosimendan on Clinical Status in Acutely Decompensated Heart Failure. American Heart Association Scientific Sessions; Dallas, 2005
  8. Avgeropoulou C, Andreadou I, Markantonis-Kyroudis S, Demopoulou M, Missovoulos P, Androulakis A, Kallikazaros I: The Ca+2 sensitizer Levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail. 7(5):882-7, 2005. 9. de Lemos JA, McGuire DK, Drazner MH: B-type natriuretic peptide in cardiovascular disease. Lancet. 362(9380):316–22, 2003
  9. McLean AS, Huang SJ, Tang B and Nalos M: Levosimendan benefits critically ill patients with decompensated heart failure assessed with plasma B-type natriuretic peptide (BNP) and LVEF. Critical Care. 7 (Suppl 2):P056, 2003
  10. Innes CA, Wagstaff AJ: Levosimendan. A review of its use in the management of acute decompensated heart failure. Drugs. 63(23): 2651-2671, 2003
  11. Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 23 (18): 1422-32, 2002.